Ammonia-Producing Bacteria of the Human Gut
Where They Live Along the GI Tract and How They Relate to Cancer
The gut microbiota generates ammonia by two routes: ureolysis (urease splits host urea into ammonia and CO₂) and proteolytic deamination (fermentation of protein and amino acids). The heaviest producers cluster in the mouth, stomach and distal colon, and several of them are also implicated in cancer, ranging from the WHO Group 1 gastric carcinogen Helicobacter pylori to genotoxin- and toxin-producing colonic species. This post maps the major taxa to their location and to the strength of their cancer evidence, including preclinical in vivo data.
Two Microbial Routes to Ammonia
Understanding why a species produces ammonia matters, because it dictates where in the gut it is active and what it is responding to. Urease-driven producers are limited by urea availability; proteolytic producers are limited by protein and amino-acid supply which is precisely why high-protein and high-fat, dysbiotic diets amplify colonic ammonia. Collectively the gut community hydrolyzes roughly 15–30% of the urea the body synthesizes.
Ammonia Generation Mechanisms
Ureolysis: Microbial ureases hydrolyze host-derived urea diffusing into the lumen into ammonia and carbon dioxide. Classic in H. pylori, Klebsiella, Proteus and oral streptococci.
Amino-Acid Deamination: Proteolytic anaerobes ferment peptides and amino acids e.g. via the Stickland reaction in clostridia, releasing free ammonia. Dominant in the distal colon.
Substrate-Driven: Proteolytic output scales with dietary protein and fat load, so obesity- and diet-induced dysbiosis markedly increases luminal ammonia (millimolar concentrations).
The Map: Taxa, Location and Cancer Evidence
The table below lists the major ammonia-producing taxa in anatomical order, from mouth to colon, with their mechanism and a summary of cancer involvement. Colour tags in the final column indicate the strength of the cancer link.
| Bacterium | Ammonia mechanism | GI location (mouth → colon) | Cancer involvement (incl. preclinical in vivo) |
|---|---|---|---|
| Streptococcus salivarius / S. vestibularis | Urease (~50% of strains; dominant oral ureolytic species) | Mouth — tongue dorsum, oral mucosa, saliva; swallowed onward | ● Weak / indirect; oral streptococci associated with oral and esophageal carcinogenesis via inflammation. |
| Actinomyces naeslundii | Urease (urea → ammonia in plaque) | Mouth — dental plaque, biofilm | ● Limited; associational only. |
| Helicobacter pylori | Very potent urease (acid-neutralizing survival factor) | Stomach (gastric mucosa) | ● Strongest link — WHO Group 1 gastric carcinogen. Ammonia disrupts tight junctions, damages epithelium, drives proliferation; urease itself promotes angiogenesis / HIF-1α. Also MALT lymphoma. |
| Streptococcus anginosus | Proteolytic / ammonia-generating | Mouth → stomach (ectopic gastric colonization) | ● Strong preclinical. Promotes gastritis, atrophy, metaplasia and gastric tumorigenesis in mice (Cell, 2024); GSDME-pyroptosis, increased proliferation / invasion. |
| Klebsiella pneumoniae | Potent ureC urease | Small intestine → colon (blooms in dysbiosis / IBD) | ● Strong preclinical. ST11 strains exacerbate colitis-associated CRC in mice; T6SS drives inflammation / tumour growth; gut→liver translocation promotes HCC in mice. |
| Proteus mirabilis | Highly potent urease | Colon (dysbiotic expansion) | ● Preclinical / associational; enriched in HCC-promoting faecal transplants in mice; pro-inflammatory. |
| Morganella morganii | Urease + proteolytic | Colon (enriched in IBD / CRC) | ● Strong preclinical. Produces indolimine genotoxins → DNA double-strand breaks; worsens colon tumorigenesis in gnotobiotic mice, abolished in indolimine-null mutants (Science, 2022). |
| Fusobacterium nucleatum | Proteolytic / amino-acid deamination | Mouth (oral commensal) → ectopic colon | ● Strong preclinical + human. Enriched in adenoma / carcinoma; FadA→Wnt/β-catenin, inflammation (IL-1β/6/8, TNF-α), Fap2 immune evasion, chemoresistance. |
| Bacteroides fragilis — enterotoxigenic (ETBF) | Proteolytic / deamination (+ BFT toxin) | Distal colon | ● Strong preclinical. BFT → spermine-oxidase ROS, DNA damage, colon tumorigenesis in mice; increased JMJD2B / stemness, Wnt/β-catenin. |
| Bacteroides ovatus & B. vulgatus | Proteolytic / amino-acid deamination (substrate-driven, not urease) | Distal colon; enriched by high-fat diet / dysbiosis | ● Context-dependent, newly mechanistic. In HFD/obesity mouse CRC model, their ammonia disrupts TGF-β tumour suppression — caspase-3 cleaves SPTBN1, ammonia–SPTBN1 adducts trap SMAD3 and drive proinflammatory cytokines (2025). Also BSH → carcinogenic bile acids. But strain-dependent: B. vulgatus can ameliorate HFD obesity; B. ovatus N-methylserotonin can inhibit CRC. |
| Clostridium perfringens | Proteolytic / amino-acid deamination (Stickland reaction); not a urease producer | Small intestine → distal colon (spore-former; blooms in dysbiosis). Essentially absent from mouth / stomach. | ● Weak & bidirectional. Mainly a bacteraemia marker of pre-existing GI / hepatobiliary cancer (tumour breaches barrier → translocation), not a proven driver; α-toxin causes damage / inflammation. Conversely, its enterotoxin (CPE) is an anticancer tool — targets claudin-3/4 overexpressed in colon/breast/ovarian tumours; CPE suicide-gene therapy eradicated colon carcinoma in mice. |
| Other urease⁺ opportunists: Salmonella, Yersinia enterocolitica, Staph. saprophyticus, Ureaplasma urealyticum | Urease | Transient, stomach → colon | ● Mostly minimal; chronic Salmonella linked to gallbladder / colon cancer. |
| Minor proteolytic contributors: Propionibacterium, Lactobacillus, Veillonella | Proteolysis / deamination | Colon (Veillonella also mouth) | ● Generally neutral-to-protective; not established drivers. |
Reading the Map, Mouth to Colon
Ammonia production is not evenly distributed along the gut. Each compartment has its own dominant producers, substrates and clinical stakes.
Mouth: the first ureolytic station
Saliva is rich in urea, and Streptococcus salivarius (the most abundant, most ureolytic tongue-dorsum coloniser) together with Actinomyces naeslundii hydrolyse it to ammonia, buffering plaque acid. This is largely protective for teeth, and the cancer link is weak but these organisms are swallowed continuously and seed the rest of the tract. Oral Fusobacterium nucleatum also originates here before its consequential migration to the colon.
Key point: an oral commensal in the mouth can become a pathobiont downstream.
Stomach: where ammonia is a proven carcinogenesis promoter
The stomach is the clearest “ammonia → cancer” story. Helicobacter pylori uses an exceptionally potent urease to survive gastric acid, and the resulting ammonium hydroxide is directly implicated in epithelial injury, tight-junction breakdown and hyperproliferation. H. pylori is a WHO Group 1 carcinogen for gastric adenocarcinoma and MALT lymphoma.
Streptococcus anginosus: an oral organism that can ectopically colonise the stomach and independently promotes gastritis, atrophy, metaplasia and gastric tumours in mice, making it an emerging gastric pathobiont.
Small intestine & colon — the ammonia heartland
The distal colon is where undigested protein reaches the densest microbial community, so it is the dominant site of both ureolytic and proteolytic ammonia. Urease-driven Enterobacteriaceae (Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii) bloom under dysbiosis and IBD, while proteolytic anaerobes (Bacteroides, Fusobacterium, Clostridium) ferment amino acids.
This is also where the strongest colorectal cancer mechanisms live: the indolimine genotoxins of M. morganii, the BFT toxin of enterotoxigenic B. fragilis, the FadA/Fap2 machinery of F. nucleatum, and the ammonia–TGF-β axis of B. ovatus/vulgatus.
When Ammonia Itself Is the Weapon: the TGF-β Mechanism
For most of these organisms the demonstrated carcinogenic effector is a toxin or genotoxin, with ammonia as a shared metabolic co-factor. But two settings pinpoint ammonia itself as the driver: the H. pylori gastric story above, and a 2025 study showing that colonic ammonia sabotages the TGF-β tumour-suppressor pathway.
Ammonia → SPTBN1 cleavage → TGF-β failure
In a high-fat-diet mouse model, dysbiosis enriched ammonia-producing Bacteroides ovatus and B. vulgatus. The ammonia they release promotes caspase-3–mediated cleavage of SPTBN1 (βII-spectrin), the adaptor that normally partners with SMAD3.
Normally SPTBN1–SMAD3 travels to the nucleus to switch on tumour-suppressive TGF-β target genes. Ammonia disrupts this: SMAD3 is trapped at the membrane and cytoplasm, and the cleaved SPTBN1 fragments form adducts with ammonia that drive proinflammatory cytokines.
Net effect: tumour-suppressor signalling is switched off while inflammation is switched on — completing a diet → dysbiosis → ammonia → disrupted tumour suppression pathway.
Two Important Caveats
Bacteroides ovatus and B. vulgatus are context-dependent
These species have a genuine Jekyll-and-Hyde literature. Under high-fat/dysbiotic conditions they act as ammonia producers that promote CRC via TGF-β disruption and bile-salt-hydrolase-driven carcinogenic bile acids. Yet in other settings the same species are protective: B. vulgatus supplementation ameliorates high-fat-diet obesity and hyperlipidaemia in mice, and B. ovatus-derived N-methylserotonin can inhibit colorectal cancer.
Their net effect is strain- and context-dependent, determined by substrate load and community composition, not by the species label alone.
Clostridium perfringens: marker, not driver, and a potential therapy
Ammonia route: proteolytic amino-acid deamination via the Stickland reaction. It is not a urease producer, so its output tracks protein load rather than urea.
Cancer link is bidirectional: clinically it is mostly a bacteraemia marker of pre-existing GI or hepatobiliary tumours (a tumour breaches the mucosal barrier and lets the organism translocate), rather than a demonstrated carcinogen.
Why This Matters & What It Doesn't Prove
⚠️ Interpreting the Evidence
The ammonia–cancer relationship is best understood as one thread within a web of protein-fermentation metabolites (alongside phenols, indoles, N-nitroso compounds and hydrogen sulfide) and toxin/genotoxin pathways, not a single-cause story.
Key points:
- Only for H. pylori (stomach) and the colonic TGF-β/SPTBN1 axis is ammonia itself firmly identified as a carcinogenesis promoter.
- For most colonic species, inflammation, toxins and genotoxins are the proven effectors; ammonia is a co-contributor via cytotoxicity, hyperproliferation and barrier disruption.
- Much of the strongest data is preclinical (mouse/gnotobiotic); human causal validation is still developing.
- The same species can be harmful or protective depending on strain, diet and community context.
Summary
- Two mechanisms, mapped to location: ureolysis dominates the mouth (S. salivarius) and stomach (H. pylori); proteolytic deamination dominates the distal colon.
- The clearest ammonia-driven cancer is H. pylori in the stomach (WHO Group 1 carcinogen).
- The strongest colonic drivers with preclinical in vivo evidence are M. morganii (indolimine genotoxins), enterotoxigenic B. fragilis (BFT), F. nucleatum (FadA/Fap2) and K. pneumoniae.
- A novel ammonia-specific pathway links high-fat diet → B. ovatus/vulgatus → ammonia → caspase-3/SPTBN1 cleavage → TGF-β disruption.
- Two organisms defy the pattern: B. ovatus/vulgatus are context-dependent, and C. perfringens is largely a cancer marker whose enterotoxin is being developed as a therapy.
⚠️ Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. It describes mechanistic and preclinical research and should not be interpreted as diagnosis, treatment recommendations, or a basis for self-testing. Always consult qualified healthcare professionals for personalised medical advice, cancer screening and treatment decisions.
Key considerations:
- Presence of a given bacterium does not by itself predict cancer risk; risk is multifactorial.
- Much of the cited mechanism comes from animal and cell-based models, not human trials.
- Microbiome and dietary interventions should follow evidence-based, medically supervised approaches.
- Current cancer screening guidelines remain the standard of care.
References
1. Konieczna I, Zarnowiec P, Kwinkowski M, et al. Bacterial urease and its role in long-lasting human diseases. Curr Protein Pept Sci / PLoS Pathog (Microbial Urease in Health and Disease). PMC4263730
2. Keep calm with ammonia-producing microbiota. Nature Reviews Microbiology. doi:10.1038/s41579-023-00996-x
3. Gut microbiota and dynamics of ammonia metabolism in liver disease. npj Gut and Liver. doi:10.1038/s44355-024-00011-x
4. Shen TD, Albenberg L, Bittinger K, et al. Engineering the gut microbiota to treat hyperammonemia. J Clin Invest. PMC4563680
5. Chen YY, Burne RA. Streptococcus salivarius urease: genetic and biochemical characterization. J Bacteriol. PMC173805
6. Tsujii M, Kawano S, Tsuji S, et al. Ammonia: a possible promotor in Helicobacter pylori-related gastric carcinogenesis. Cancer Lett. doi:10.1016/0304-3835(92)90207-C
7. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int J Mol Sci. PMC9917787
8. Fu K, Cheung AHK, Wong CC, et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024. doi:10.1016/j.cell.2024.01.004
9. Two ST11 Klebsiella pneumoniae strains exacerbate colorectal tumorigenesis in a colitis-associated mouse model. PMC8496539
10. Gut–liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice. Nature Microbiology. doi:10.1038/s41564-024-01890-9
11. Cao Y, Oh J, Xue M, et al. Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites (Morganella morganii indolimines). Science. 2022;378(6618). doi:10.1126/science.abm3233
12. Goodwin AC, Destefano Shields CE, Wu S, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. PNAS. doi:10.1073/pnas.1010203108
13. The Mechanism of Bacteroides fragilis Toxin Contributes to Colon Cancer Formation. PMC7444842
14. Fusobacterium nucleatum in Colorectal Cancer: Ally Mechanism and Targeted Therapy Strategies. PMC11979337
15. Bhowmick K, Yang X, Mohammad T, et al. Microbial metabolite ammonia disrupts TGF-β signaling to promote colon cancer. J Biol Chem. 2025;301(6):108559. PMC12155590
16. Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer. Nature Communications. PMC9918522
17. Bacteroides vulgatus ameliorates high-fat diet-induced obesity through modulating intestinal serotonin synthesis and lipid absorption in mice. Gut Microbes. PMC11583587
18. Bacteroides ovatus-derived N-methylserotonin inhibits colorectal cancer via the HTR1D-mediated cAMP-PKA-NF-κB signaling axis. PMC12682799
19. Clostridium perfringens bacteremia associated with colorectal cancer in an elderly woman. PMC7928247
20. Clostridium perfringens Enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells via claudin-3 and -4. PMC1615652
21. Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy. BMC Cancer. PMC5307849
22. Ammonia production by human faecal bacteria, and the enumeration, isolation and characterization of bacteria capable of growth on peptides and amino acids. BMC Microbiol. PMID:23312016
Abbreviations: GI: Gastrointestinal; CRC: Colorectal Cancer; HCC: Hepatocellular Carcinoma; IBD: Inflammatory Bowel Disease; HFD: High-Fat Diet; ETBF: Enterotoxigenic Bacteroides fragilis; BFT: Bacteroides fragilis Toxin; CPE: Clostridium perfringens Enterotoxin; BSH: Bile Salt Hydrolase; T6SS: Type VI Secretion System; TGF-β: Transforming Growth Factor Beta; SPTBN1: Spectrin Beta Non-Erythrocytic 1; ROS: Reactive Oxygen Species; MALT: Mucosa-Associated Lymphoid Tissue.
This article integrates review literature, mechanistic studies and preclinical in vivo investigations. Compiled July 2026.
%20(3).png)
No comments:
Post a Comment